The History of Amphetamines: From Discovery to Medical Regulation

Most patients I see who are dependent on amphetamines or methamphetamine are surprised to learn this drug was once sold in drugstores without a prescription. That context actually helps in treatment. When someone understands that a billion-dollar pharmaceutical industry spent decades marketing this molecule as safe and beneficial, the shame around addiction shifts. It becomes easier to talk about what happened physiologically, and harder to frame it as a personal failure.

The First Synthesis: Who Actually Discovered Amphetamine?

The story starts in 1887, not 1927. Romanian chemist Lazăr Edeleanu first synthesised the compound beta-phenyl-isopropylamine while working in Berlin. He called it phenylisopropylamine, noted no obvious pharmacological use, and moved on. The molecule sat largely ignored for four decades.

In 1927, Los Angeles chemist Gordon Alles returned to it. He was looking for a cheaper, synthesisable substitute for ephedrine, which Eli Lilly had turned into a blockbuster asthma treatment. On June 3, 1929, Alles injected himself with 50 milligrams, roughly five times the dose later recommended. His nose cleared. His blood pressure climbed. He felt, as he recorded it, “a feeling of well being.” He talked too much at dinner. He did not sleep.

That self-experiment launched the amphetamine era.

In 1932, Alles patented amphetamine sulphate and amphetamine hydrochloride in the United States. He then approached Philadelphia pharmaceutical firm Smith, Kline and French, who had separately patented a Benzedrine inhaler. The two interests merged, and what followed was one of the most aggressive drug marketing campaigns of the twentieth century.

The name “amphetamine” itself came later. The Council on Pharmacy and Chemistry of the American Medical Association coined the generic term from the full chemical name, alpha-methylphenethylamine. That is why early publications refer only to “Benzedrine,” not amphetamine.

Benzedrine and the Golden Age of Unregulated Stimulants

Smith, Kline and French brought Benzedrine to market in 1935. The official indications included narcolepsy, mild depression, and post-encephalitic Parkinsonism. Within a few years the list had expanded to include hay fever, seasickness, alcohol hangovers, radiation sickness, and persistent hiccups. At the height of its early promotion, over thirty medical conditions appeared on the approved uses list.

The inhaler came first. It contained 325 milligrams of amphetamine base on a strip of paper inside a small tube. Users discovered immediately that cracking the inhaler open and swallowing or soaking the paper produced an intense stimulant effect. Abuse reports appeared in medical literature within three years of launch.

Amphetamine in World War II — Mass Military Distribution

This is where supply became truly industrial. Both Allied and Axis powers distributed amphetamines to troops. The British military issued Benzedrine tablets to bomber crews flying long-range missions. American soldiers received them to counter fatigue during sustained combat operations. Japanese kamikaze pilots were given methamphetamine, a close chemical relative, before missions. German forces used Pervitin, also methamphetamine, so widely it was nicknamed “Panzerschokolade” (tank chocolate).

Estimates suggest Allied forces alone received 72 million Benzedrine tablets during the war. When soldiers returned home, a significant number continued use. By the late 1940s, dependence had moved from anecdotal reports in medical journals to a recognised clinical pattern in general practice.

The Pharmacology Behind the History — How Amphetamine Works

History without mechanism is incomplete. Amphetamine is a phenethylamine that acts primarily as a releasing agent at monoamine transporters, specifically the dopamine transporter (DAT), norepinephrine transporter (NET), and to a lesser degree the serotonin transporter (SERT).

Here is what actually happens at the neuronal level. Amphetamine enters the presynaptic neuron, reverses the DAT and NET transporters, and floods the synapse with dopamine and norepinephrine. This is mechanistically different from cocaine, which simply blocks reuptake. Amphetamine forces active release. The result is a larger and more sustained dopamine surge in the nucleus accumbens, the brain’s reward centre.

Dopamine, the Reward System, and Why Dependence Develops

The nucleus accumbens sits within the mesolimbic pathway, the circuit that encodes motivation, reward anticipation, and habit formation. When amphetamine floods this circuit repeatedly, the brain compensates by downregulating dopamine D2 receptors and reducing baseline dopamine synthesis. This is neuroadaptation.

The clinical consequence is predictable. The user needs more amphetamine to feel normal, not just to get high. Stopping produces a pronounced dysphoria, fatigue, hypersomnia, and anhedonia, the clinical presentation of amphetamine withdrawal. This is the Koob-Volkow allostatic model in action: the brain’s reward set-point shifts downward, and the drug becomes necessary to reach baseline rather than to exceed it.

The enzyme monoamine oxidase (MAO) normally degrades dopamine in the synapse. Amphetamine partially inhibits MAO-A, which extends dopamine’s active time. Hepatic metabolism involves CYP2D6, a cytochrome P450 enzyme, producing 4-hydroxymethamphetamine and norephedrine as primary metabolites. CYP2D6 genetic variants, including the poor metaboliser phenotype, affect how quickly individuals clear the drug and therefore their vulnerability to toxicity.

d-Amphetamine Versus l-Amphetamine — Why the Isomer Matters

Amphetamine has a single chiral centre, meaning it exists as two mirror-image forms. The dextro isomer (d-amphetamine) is three to four times more potent at CNS dopamine release than the levo isomer (l-amphetamine). This is why pharmaceutical manufacturers progressively moved toward d-amphetamine formulations for ADHD treatment: more CNS effect per milligram, less peripheral cardiovascular stimulation from the l-isomer.

The distinction between amphetamine and methamphetamine is worth naming here. Methamphetamine has an added methyl group on the nitrogen atom. This makes it more lipid-soluble, allowing faster penetration of the blood-brain barrier, a more rapid onset, and a harder dopamine hit. For a full comparison, see the breakdown of amphetamine versus methamphetamine differences.

The Post-War Epidemic and Psychiatric Overuse

The 1950s saw amphetamine prescribing reach levels that are difficult to comprehend today. In 1959, US manufacturers produced an estimated 8 billion amphetamine tablets. The drug was prescribed for obesity, fatigue, depression, and broadly for “nervousness.” Housewives received it from general practitioners as a slimming aid. College students used it openly as a study drug. The phrase “pep pills” entered everyday language.

Psychiatry had a complicated relationship with amphetamines during this period. The drug genuinely lifted mood in depressed patients, which initially seemed like a clinical win. The problem was that tolerance to the antidepressant effect developed faster than tolerance to cardiovascular side effects. Patients escalated doses. Psychosis emerged. The amphetamine psychosis syndrome, clinically indistinguishable from acute paranoid schizophrenia and involving the same dopaminergic hyperstimulation of the mesocortical pathway, began appearing regularly in psychiatric admissions.

Charles Bradley and the Discovery of Amphetamine’s Paradoxical Effect in Children

In 1937, paediatrician Charles Bradley at Emma Pendleton Bradley Home in Rhode Island gave Benzedrine to thirty children with behavioural difficulties. He expected nothing in particular. What he found was a paradoxical calming effect: children who had been impulsive, disruptive, and inattentive became focused and tractable. Academic performance improved dramatically in roughly half the group.

Bradley published his results. They were largely ignored for fifteen years. We now understand the mechanism: in ADHD, frontal lobe dopamine and norepinephrine tone is insufficient to modulate subcortical impulsivity. Amphetamine restores that tone, producing what looks paradoxically like sedation but is actually executive function coming online. The prefrontal cortex, heavily dependent on both DAT and NET activity, is the primary therapeutic target.

Bradley’s 1937 findings are the direct ancestor of modern ADHD pharmacology. Adderall, Vyvanse, and Dexedrine all trace their clinical rationale to that Rhode Island study.

Regulatory History — From Open Sale to Schedule II

The first formal US restriction came in 1951, when the Durham-Humphrey Amendment required a prescription for amphetamines. It did not limit prescribing volume. Physicians continued prescribing at massive scale.

The real watershed was the US Controlled Substances Act of 1970, which placed amphetamines in Schedule II, meaning high abuse potential with accepted medical use, requiring triplicate prescription forms in many states. This dramatically reduced prescribing. The 1971 UN Convention on Psychotropic Substances extended scheduling internationally, placing amphetamines in Schedule II of that framework.

In the United Kingdom, amphetamines were classified under the Misuse of Drugs Act 1971 as Class B substances. Thailand, relevant to our patient population at Phuket Island Rehab, classifies amphetamines as Category 1 controlled substances under the Narcotic Drugs Act, the same category as heroin, with severe criminal penalties for production and distribution.

Lisdexamfetamine — The Modern Pharmaceutical Response to Abuse Liability

The most clinically significant recent development in amphetamine pharmacology is lisdexamfetamine (Vyvanse). It is the first d-amphetamine prodrug approved for ADHD in children, adolescents, and adults. The mechanism is deliberately engineered to reduce abuse potential.

Lisdexamfetamine is l-lysine covalently bonded to d-amphetamine. The compound is pharmacologically inactive until hydrolysis by peptidases in red blood cells cleaves the lysine, releasing d-amphetamine into circulation. This hydrolysis is rate-limited, meaning the conversion cannot be accelerated by taking more of the drug. Crushing and snorting lisdexamfetamine does not produce a faster or larger effect, unlike standard amphetamine formulations.

The result is a flatter pharmacokinetic curve: a slower Tmax (time to peak plasma concentration), lower Cmax (peak plasma concentration), and an extended therapeutic window compared to immediate-release amphetamine. This slower rise in plasma concentration translates directly to a reduced dopamine surge rate in the nucleus accumbens, which is the key variable in abuse liability.

Amphetamine and the Illicit Market — From Diverted Pharmaceuticals to Methamphetamine

As pharmaceutical amphetamine became harder to obtain, two things happened. Illicit methamphetamine production expanded to fill demand, and diversion of prescription stimulants became a parallel supply chain. By the 1980s and 1990s, methamphetamine had largely displaced pharmaceutical amphetamine in street drug markets across North America, East Asia, and Southeast Asia.

In Thailand and across the broader region, methamphetamine tablets known as yaba (the shabu drug) became the dominant stimulant, displacing pharmaceutical amphetamine entirely. The chemistry and neuropharmacology overlap substantially with the original Benzedrine formulations, but methamphetamine’s greater lipid solubility produces a more intense and faster-onset dopamine surge, which correlates with higher addiction liability.

The historical arc from Benzedrine inhaler cracking in the 1930s to crystal meth effects today is direct. The molecule changed incrementally. The fundamental mechanism, flooding the mesolimbic dopamine system beyond its capacity to self-regulate, did not change at all.

What the History of Amphetamine Tells Us About Addiction Medicine

Every major wave of stimulant harm followed the same pattern. A molecule with genuine medical utility gets promoted aggressively. Abuse potential is minimised or ignored. Prescribing or availability scales to population level. Addiction, psychosis, and cardiovascular harm follow. Restriction comes decades later than the clinical evidence warranted.

This pattern recurred with pharmaceutical opioids in the 1990s. It is visible now in debates about prescription stimulant prescribing for ADHD. The history of cocaine, another monoamine reuptake inhibitor promoted as a therapeutic wonder drug before its harms became undeniable, follows the same arc.

Knowing this history does not mean ADHD medications are harmful for appropriate patients. It means the clinical obligation is accurate risk stratification, not reflexive permissiveness or reflexive prohibition.

The pattern I see clinically is not usually someone who started using amphetamines recreationally and immediately lost control. Most patients describe a period of functional use that gradually became non-negotiable. Work performance or energy management was the initial driver. Then the dose crept up. Sleep deteriorated. Stopping felt impossible. By DSM-5 criteria, stimulant use disorder is diagnosed when two or more of eleven specified criteria are present over a twelve-month period, including tolerance, withdrawal, unsuccessful attempts to cut down, and continued use despite harm. The condition exists on a severity spectrum from mild to severe, and severity affects treatment approach.

At Phuket Island Rehab, we work with patients who have developed stimulant use disorder through prescription medication misuse, illicit amphetamine use, and methamphetamine dependence. The treatment framework includes medically supervised stabilisation, evidence-based psychological intervention addressing the dopamine dysregulation underlying the disorder, and structured relapse prevention. If you recognise the pattern described above in yourself or someone close to you, the clinical evidence strongly supports that earlier treatment produces better outcomes. You can find out more about amphetamine addiction treatment options available in Thailand.

Amphetamine went from an obscure synthesis in 1887 to one of the most widely distributed drugs on earth within fifty years, not because of rigorous clinical evidence, but because of aggressive pharmaceutical marketing, wartime logistics, and a cultural appetite for productivity-enhancing stimulants. The neuropharmacology was sound in one narrow sense: amphetamine does release dopamine and norepinephrine, and those actions do produce alertness, focus, and mood elevation. What manufacturers did not disclose, and what took decades of clinical experience to establish, was that the same mechanism produces tolerance, dependence, psychosis, and cardiovascular harm at scale. Every regulatory milestone, from the Durham-Humphrey Amendment in 1951 to Schedule II in 1970, came after the harm was already widespread.

The practical lesson for anyone encountering amphetamines today, whether in prescription form, in the illicit stimulant market, or in treatment settings, is that mechanism does not change based on marketing. D-amphetamine forces dopamine release in the mesolimbic system. Do that repeatedly, and the system adapts in ways that make stopping painful and the drug feel necessary. Lisdexamfetamine’s prodrug engineering reduces but does not eliminate this risk. Methamphetamine intensifies it. The clinical history from Charles Bradley’s 1937 paediatric trial to modern ADHD prescribing guidelines represents genuine progress. The history from the Benzedrine inhaler to global methamphetamine epidemic represents what happens when that progress is outpaced by commercial or illicit supply. As John A. Smith of Phuket Island Rehab puts it: “The patients I see today are not a new problem. They are the end point of a very old story about a molecule that works exactly as advertised, until it doesn’t.”

When was amphetamine first synthesised?

Amphetamine was first synthesised in 1887 by Romanian chemist Lazăr Edeleanu in Berlin, though it was not recognised as pharmacologically significant at that time. Gordon Alles independently resynthesised the compound in 1927 while searching for an ephedrine substitute, and it was Alles’s research that led to commercial development. Most histories cite 1887 as the first synthesis and 1927 as the start of its pharmaceutical history.

Why was amphetamine originally prescribed, and what conditions was it used for?

Amphetamine was first marketed in 1935 for narcolepsy, mild depression, and post-encephalitic Parkinsonism. Within a few years, the approved indications expanded to include obesity, hay fever, seasickness, fatigue, alcohol hangovers, and over thirty other conditions. The aggressive expansion of its indications reflected commercial pressure more than clinical evidence, and many of those early uses would not survive modern regulatory scrutiny.

How does amphetamine differ from methamphetamine chemically and pharmacologically?

Methamphetamine has an additional methyl group on the nitrogen atom of the amphetamine molecule. This structural difference makes methamphetamine more lipid-soluble, meaning it crosses the blood-brain barrier faster and produces a more rapid and intense dopamine surge in the nucleus accumbens. The result is a higher abuse liability and greater neurotoxic potential with chronic use. You can read a detailed comparison of amphetamine versus methamphetamine for more on how these two molecules differ in practice.

When did governments start restricting amphetamines, and why did it take so long?

The first US prescription requirement came in 1951, followed by Schedule II classification under the Controlled Substances Act in 1970. The delay was driven by a combination of commercial interests, widespread cultural acceptance, and the genuine therapeutic utility of the drug in specific conditions. Addiction and psychosis were documented in medical literature from the early 1940s, but regulatory action lagged by decades. The 1971 UN Convention on Psychotropic Substances then extended scheduling internationally.

Is the amphetamine in ADHD medication the same as street amphetamine?

The active molecule is related: Adderall contains mixed amphetamine salts (75% d-amphetamine, 25% l-amphetamine), and Vyvanse is a d-amphetamine prodrug. The pharmacological mechanism, DAT and NET reversal with dopamine and norepinephrine release, is the same. What differs is formulation: extended-release and prodrug designs flatten the pharmacokinetic curve, reducing the rate of dopamine rise that drives euphoria and abuse liability. For someone with a personal or family history of stimulant use disorder, this distinction matters clinically and should be discussed with a prescribing physician.

What is amphetamine psychosis, and how long does it last?

Amphetamine psychosis is a psychiatric syndrome caused by excessive dopaminergic stimulation of the mesocortical pathway, producing paranoid delusions, auditory and visual hallucinations, and agitation that is clinically indistinguishable from acute paranoid schizophrenia. It typically emerges with high doses or chronic use. Symptoms can persist for days to weeks after the last dose, depending on how long and how heavily the drug was used. It requires emergency psychiatric assessment and, in most cases, antipsychotic medication during the acute phase.

What is lisdexamfetamine and how does it reduce abuse potential?

Lisdexamfetamine is d-amphetamine bonded to l-lysine, forming a pharmacologically inactive prodrug. It becomes active only when peptidases in red blood cells cleave the lysine group, releasing d-amphetamine slowly into circulation. Because this conversion is rate-limited, taking more of the drug does not speed it up or increase the peak plasma concentration. The result is a slower Cmax and a flatter dopamine release curve, which translates directly to lower abuse liability compared to immediate-release amphetamine formulations.